Yeh Cheng-Fa, Chan Ti-Chun, Ke Hung-Lung, Chen Tzu-Ju, Wu Li-Ching, Lee Hsiang-Ying, Wei Yu-Ching, Wu Wen-Jeng, Li Chien-Feng, Li Wei-Ming
Division of General Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan.
Department of Environment Engineering and Science, Chia Nan University of Pharmacy and Science, Tainan 717, Taiwan.
Biomedicines. 2021 Aug 20;9(8):1054. doi: 10.3390/biomedicines9081054.
We investigated the association of receptor tyrosine kinase-like orphan receptor 2 (ROR2) expression with clinicopathological features and oncologic outcomes in large urothelial carcinoma (UC) of the upper tract (UTUC) and urinary bladder (UBUC) cohorts. Through transcriptomic profiling of a published dataset (GSE31684), ROR2 was discovered to be the most upregulated gene during UC progression, focusing on the JNK cascade (GO:0007254). Initially, the evaluation of mRNA expression in 50 frozen UBUCs showed significantly upregulated levels in high-stage UC. Moreover, high ROR2 immunoexpression significantly correlated with high tumor stage, high tumor grade, lymph node metastasis, and vascular invasion (all < 0.05). In multivariate analysis, after adjusting for standard clinicopathological features, ROR2 expression status was an independent prognosticator of cancer-specific survival and metastasis-free survival in UTUC and UBUC (all < 0.01). In the subgroup analysis, it also significantly predicted bladder tumor recurrence in non-muscle invasive UBUC. Furthermore, the GO enrichment analysis showed that fatty acid, monocarboxylic acid, carboxylic acid metabolic processes, negative regulation of neutrophil migration, and negative regulation of granulocyte and neutrophil chemotaxis were significantly enriched by ROR2 dysregulation. In conclusion, high ROR2 immunoexpression was associated with aggressive pathological characteristics in UC and independently predicted worse prognosis, suggesting it could play roles in clinical risk stratification and therapy decisions.
我们研究了受体酪氨酸激酶样孤儿受体2(ROR2)表达与上尿路尿路上皮癌(UTUC)和膀胱尿路上皮癌(UBUC)大型队列的临床病理特征及肿瘤学结局之间的关联。通过对已发表数据集(GSE31684)进行转录组分析,发现ROR2是UC进展过程中上调最为明显的基因,主要涉及JNK级联反应(GO:0007254)。最初,对50例冷冻UBUC样本的mRNA表达评估显示,高分期UC中ROR2水平显著上调。此外,ROR2高免疫表达与高肿瘤分期、高肿瘤分级、淋巴结转移及血管侵犯均显著相关(均P<0.05)。多因素分析中,在调整标准临床病理特征后,ROR2表达状态是UTUC和UBUC患者癌症特异性生存及无转移生存的独立预后因素(均P<0.01)。亚组分析中,其也是非肌层浸润性UBUC患者膀胱肿瘤复发的显著预测因素。此外,基因本体(GO)富集分析显示,ROR2失调显著富集了脂肪酸、一元羧酸、羧酸代谢过程、中性粒细胞迁移的负调控以及粒细胞和中性粒细胞趋化性的负调控。总之,ROR2高免疫表达与UC侵袭性病理特征相关,并独立预测较差预后,提示其可在临床风险分层及治疗决策中发挥作用。